Additional competition in PNH will come from Novartis’ recently approved oral therapy Fabhalta (iptacopan), a targeted factor B inhibitor that in trials was shown to be more effective than ...

AZ acquired rights to danicopan as part of its $39 billion acquisition of Alexion in 2021, which also gave it Soliris and Ultomiris, and the drug is viewed as a way to shore up the PNH franchise ...

Novartis Fabhalta shows statistically significant and clinically meaningful improvements in haemoglobin in new population of patients with PNH: Basel Friday, June 13, 2025, 09:00 ...

Sanofi (NASDAQ: SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (NASDAQ:SNY) on June 12, setting a price ...

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug ...

AstraZeneca (AZ) has announced promising results from a late-stage study of its C5 complement inhibitor Ultomiris ...

SEATTLE, WA, USA I June 27, 2025 I Omeros Corporation (Nasdaq: OMER) today announced the recent submission of a Marketing Authorization Application (MAA) to ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

“This is a historic day in the decades-long fight against HIV,” Gilead CEO Daniel O’Day said in the company’s announcement.

Last week, Australia’s Therapeutic Goods Administration (TGA) approved the weight-loss drug Mounjaro to treat sleep apnoea, a ...